Abstract

BackgroundThe current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is a public health emergency and the case fatality rate in the United Kingdom is significant. Although there appear to be several early predictors of outcome, there are no currently validated prognostic models or scoring systems applicable specifically to patients with confirmed SARS-CoV-2.ObjectiveWe aim to create a point-of-admission mortality risk scoring system using an artificial neural network (ANN).MethodsWe present an ANN that can provide a patient-specific, point-of-admission mortality risk prediction to inform clinical management decisions at the earliest opportunity. The ANN analyzes a set of patient features including demographics, comorbidities, smoking history, and presenting symptoms and predicts patient-specific mortality risk during the current hospital admission. The model was trained and validated on data extracted from 398 patients admitted to hospital with a positive real-time reverse transcription polymerase chain reaction (RT-PCR) test for SARS-CoV-2.ResultsPatient-specific mortality was predicted with 86.25% accuracy, with a sensitivity of 87.50% (95% CI 61.65%-98.45%) and specificity of 85.94% (95% CI 74.98%-93.36%). The positive predictive value was 60.87% (95% CI 45.23%-74.56%), and the negative predictive value was 96.49% (95% CI 88.23%-99.02%). The area under the receiver operating characteristic curve was 90.12%.ConclusionsThis analysis demonstrates an adaptive ANN trained on data at a single site, which demonstrates the early utility of deep learning approaches in a rapidly evolving pandemic with no established or validated prognostic scoring systems.

Highlights

  • Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China in December 2019, there have been over 229,705 confirmed cases in the United Kingdom, with a case fatality rate of 14.4% as of May 13, 2020 [1,2]

  • In the United Kingdom, the highest number of coronavirus disease (COVID-19) deaths has been reported in London [3], with many health care providers having experienced a rapid, difficult-to-predict increase in intensive therapy unit (ITU) bed requirements

  • Our aim was to provide a patient-specific, point-of-admission mortality risk prediction to help inform clinical management decisions at the earliest opportunity. The contribution of this analysis is in the proof-of-concept artificial neural network (ANN) trained on data from a single site, which demonstrates the early utility of deep learning approaches in a rapidly evolving pandemic with no established or validated prognostic scoring systems

Read more

Summary

Introduction

Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China in December 2019, there have been over 229,705 confirmed cases in the United Kingdom, with a case fatality rate of 14.4% as of May 13, 2020 [1,2]. [7], and obesity [8], currently there are no validated prognostic models or scoring systems applicable to patients with SARS-CoV-2, despite attempts to delineate general predictors of mortality [9]. The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is a public health emergency and the case fatality rate in the United Kingdom is significant. There appear to be several early predictors of outcome, there are no currently validated prognostic models or scoring systems applicable to patients with confirmed SARS-CoV-2

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.